Methotrexate-lnduced liver cirrhosis: Clinical, histological and serological studies-a further 10-year follow-up

Dermatology

Volumn 192, Issue 4, 1996, Pages 343-346

  Zachariae, H ^a   Sogaard H ^a   Heickendorff, L ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Aminoterminal propeptide of type III procollagen; Liver cirrhosis; Methotrexate

Indexed keywords

FOLIC ACID ANTAGONIST; METHOTREXATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; AGED; ARTICLE; AUTOPSY; CLINICAL FEATURE; DRUG MONITORING; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PSORIASIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; MALE; METHOTREXATE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; PSORIASIS;

EID: 0029889485     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000246408     Document Type: Article

References (17)

1. Health and Public Policy Committee, American College of Physicians: Methotrexate in rheumatoid arthritis. Ann Intern Med 1987: 107:418-419.
2. Lance S. Arnold G. Goxvans J. Kaplan M: Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis: An accepted risk/ben-efit ratio. Dig Dis Sci 1985:30:104-109.
3. Wright R: Treatment of psoriasis. N Engl J Med 1995:333:259.
4. Rocnigk H. Auerbach R. Maibach H. et al: Methotrexate in psoriasis: Revised guidelines. J Am Acad Dermatol 1988:19:145-156.
5. Greaves M. Weinstein G: Treatment of psoriasis. N Engl J Med 1995;332:581-588.
6. Dooren-Greetz R. Kuijpcrs A. Mulder J. el al: Methotrexate revised: Effects of long-term treatment in psoriasis. Br J Dermatol 1994: 130:204-210.
7. Zachariae H. Sogaard H: Methotrexate-induced liver cirrhosis: A follow-up. Dermato-logica 1987:175:178-182.
8. Frei A. Zimmermann A. Weigand K: The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients w ith chronic liver disease. Hepatology 1984:4:830-834.
9. Zachariae H. Sogaard II. Heickendorff L: Serum aminoterminal propeptide of type III procollagen-A non-invasive test for liver fibrogenesis in methotrexate-treated psori-atics. Acta Derm-Venereol (Stockh) 1988:69: 241-243.
10. Zachariae H. Kragballe K. Sogaard H: Methotrexate-induced liver cirrhosis. Br J Dermatol 1980:102:407-412.
11. Zachariae H. Aslam H. Bjerring P. et al: Serum aminoterminal propeptide of type ill procolla-gen in psoriasis and psoriatic arthritis. J Am Acad Dermatol 1991:25:50-53.
12. Mitchell D. Smith A. Rowan B. et al: Serum PIIINP. dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. BrJ Dermatol 1990:122:1-7.
13. Boffa M. Smith A. Chalmers R. et al: The place of the type III procollagen aminopeptide (PIIINP) measurement in the assessment of liver damage in methotrexate (MTX)-treated psoriatic patients. Br J Dermatol 1995:133 (suppl 45): 16-17.
14. Zachariae II: Memento-MTX-induced liver cirrhosis developing ascites and liver failure due to lack of control. Ugeskr Ltegcr 1988; 150:754.
15. Gilbert S. Klintmalm G. Mentor A. Silverman A: Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. Arch Intern Med 1990;150:889-891.
16. Piccinino F. Sagnelli E. Pasquale G. Giusti G: Complications following percutaneous liver biopsy: A multicentre retrospective study on 68.276 biopsies. J Hepatol 1986:2:166-173.
17. Philips C. Cera P. Mangan T, Newman E: Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992:19:229-233.